Coca Cola 2013 Annual Report Download - page 144

Download and view the complete annual report

Please find page 144 of the 2013 Coca Cola annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 160

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160

• Charge of $6 million for North America due to costs associated with the Company detecting residues of carbendazim in
orange juice imported from Brazil for distribution in the United States. Refer to Note 17.
• Benefit of $92 million for Corporate due to a gain the Company recognized as a result of Coca-Cola FEMSA issuing
additional shares of its own stock during the period at a per share amount greater than the carrying amount of the
Company’s per share investment. Refer to Note 17.
• Charges of $3 million for Eurasia and Africa, $6 million for Europe, $2 million for Latin America, $3 million for Pacific
and a benefit of $3 million for Corporate due to changes in the structure of BPW. Refer to Note 17.
• Net charge of $1 million for Bottling Investments due to the Company’s proportionate share of unusual or infrequent items
recorded by certain of our equity method investees. Refer to Note 17.
• Net tax benefit of $25 million associated with the reversal of a valuation allowance in one of the Company’s foreign
jurisdictions as well as amounts required to be recorded for changes to our uncertain tax positions, including interest and
penalties. Refer to Note 14.
In the third quarter of 2012, the Company recorded the following transactions which impacted results:
• Charges of $48 million for North America, $1 million for Pacific, $14 million for Bottling Investments and $10 million for
Corporate due to charges related to the Company’s productivity and reinvestment program as well as other restructuring
initiatives. Refer to Note 17 and Note 18.
• Charge of $9 million for North America due to costs associated with the Company detecting residues of carbendazim in
orange juice imported from Brazil for distribution in the United States. Refer to Note 17.
• Charges of $1 million for Latin America, $1 million for North America, $2 million for Pacific and benefits of $1 million for
Eurasia and Africa and $3 million for Europe due to changes in the structure of BPW. Refer to Note 17.
• Net charge of $10 million for Bottling Investments due to the Company’s proportionate share of unusual or infrequent
items recorded by certain of our equity method investees. Refer to Note 17.
• Net charge of $7 million related to amounts required to be recorded for changes to our uncertain tax positions, including
interest and penalties. Refer to Note 14.
The Company’s fourth quarter 2012 results were impacted by two additional shipping days compared to the fourth quarter of
2011. Furthermore, the Company recorded the following transactions which impacted results:
• Charges of $1 million for Europe, $70 million for North America, $2 million for Pacific, $119 million for Bottling
Investments and $20 million for Corporate due to the Company’s productivity and reinvestment program as well as other
restructuring initiatives. Refer to Note 17 and Note 18.
• Benefit of $185 million for Corporate due to the gain the Company recognized as a result of the merger of Andina and
Polar. Refer to Note 16 and Note 17.
• Charge of $108 million for Corporate due to the loss the Company recognized on the pending sale of a majority ownership
interest in our Philippine bottling operations to Coca-Cola FEMSA. This transaction was completed in January 2013. As of
December 31, 2012, the assets and liabilities associated with our Philippine bottling operations were classified as held for
sale in our consolidated balance sheets. Refer to Note 17.
• Charge of $82 million for Corporate due to the Company acquiring an ownership interest in Mikuni for which we paid a
premium over the publicly traded market price. This premium was expensed on the acquisition date. Refer to Note 17.
• Net charge of $25 million for Bottling Investments due to the Company’s proportionate share of unusual or infrequent
items recorded by certain of our equity method investees. Refer to Note 17.
• Charge of $16 million for Corporate due to other-than-temporary declines in the fair values of certain cost method
investments. Refer to Note 16 and Note 17.
• Benefits of $1 million for Eurasia and Africa, $1 million for Latin America, $1 million for North America, $1 million for
Pacific and a charge of $1 million for Europe due to changes in the structure of BPW. Refer to Note 17.
• Net tax benefit of $124 million associated with the reversal of a valuation allowance in one of the Company’s foreign
jurisdictions as well as amounts required to be recorded for changes to our uncertain tax positions, including interest and
penalties. Refer to Note 14.
142